卡非佐米联合方案治疗初诊多发性骨髓瘤中血栓性微血管病变
CARDAMON II期试验中,8例初诊多发性骨髓瘤患者在接受含卡非佐米方案时发生血栓性微血管病变(TMA)。首次3例发生于维持治疗阶段单药卡非佐米,2例发生于KCd诱导期,3例发生于KCd巩固期。
要点
- 初诊骨髓瘤患者接受卡非佐米方案也可发生TMA,不限于复发难治人群。
- TMA发生时6/8例伴高血压,7/8例出现急性肾损伤,部分肾功能损害持续。
- 方案修订包括强化高血压管理、维持期卡非佐米阶梯给药及地塞米松预处理的措施。
核心结论
- 初诊多发性骨髓瘤患者接受卡非佐米联合方案治疗时可发生TMA,尤其见于有高血压病史者。
研究设计与样本
- CARDAMON II期试验中,8例初诊多发性骨髓瘤患者在接受卡非佐米治疗期间发生TMA事件。
主要发现
- 首次3例TMA发生于维持期单药卡非佐米,2例发生于KCd诱导期,3例发生于KCd巩固期。
- TMA发生时6/8例有高血压,7/8例有急性肾损伤,其中3例在TMA其他方面缓解后肾功能损害持续。
关键数值与推荐
- 方案修订包括:积极的高血压管理、维持期卡非佐米起始阶梯剂量(第1天20 mg/m2)后升至最大56 mg/m2、维持期卡非佐米输注前加用10 mg地塞米松预处理。
临床怎么用
- 对接受卡非佐米治疗的骨髓瘤患者应监测TMA征象,尤其关注高血压和肾功能变化。
- 维持期重启卡非佐米时可考虑阶梯剂量和地塞米松预处理,并强化降压管理。
局限性
- 样本量小,仅8例TMA事件,来自单臂II期试验,因果关系和机制尚不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Proteasome inhibitors have been associated with thrombotic microangiopathy (TMA) - a group of disorders characterised by occlusive microvascular thrombosis causing microangiopathic haemolytic anaemia, thrombocytopenia and end-organ damage. To date, carfilzomib-associated TMA has predominantly been described in relapsed/refractory myeloma patients. We report eight patients with newly diagnosed myeloma who experienced TMA events while receiving carfilzomib on the phase II CARDAMON trial. The first three occurred during maintenance single-agent carfilzomib, two occurred at induction with carfilzomib given with cyclophosphamide and dexamethasone (KCd) and three occurred during KCd consolidation. At TMA presentation 6/8 were hypertensive; 7/8 had acute kidney injury and in three, renal impairment persisted after resolution of TMA in other respects. The mechanism of carfilzomib-associated TMA remains unclear, though patients with known hypertension seem particularly susceptible. Given the first three cases occurred during maintenance after a longer than five-week treatment break, a protocol amendment was instituted with: aggressive hypertension management, carfilzomib step-up dosing (20 mg/m2 on day 1) at start of maintenance before dose escalation to 56 mg/m2 maximum, and adding 10 mg dexamethasone as premedication to maintenance carfilzomib infusions. No further TMA events occurred during maintenance following this amendment and the TMA incidence reduced from 4·2 to 1·6 per 1 000 patient cycles.
引用
- Camilleri M, Cuadrado M, Phillips E, et al. Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study. Br J Haematol. 2021. PMID: 33650100. doi:10.1111/bjh.17377
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。